Given that specifically in the settings of obesity, diabetes, fetal growth restriction, and preeclampsia, changed levels of serum apelin were observed in numerous tissues, it was hypothesized that apelin could act as a treatment target of the above pathologies. Here, APLN is linked to obesity due to melanocortin 4 receptor deficiency.